Skip to main content

Arcturus Therapeutics Holdings Inc.

ARCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001768224

No open-market purchases or sales by Arcturus Therapeutics Holdings Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arcturus Therapeutics Holdings Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arcturus Therapeutics Holdings Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arcturus Therapeutics Holdings Inc.
NameTitleLast reported holdingLast filingFilings, past year
Farrell Peter CDirector55,741Jun 15, 20261
Barlow James FDirector13,131Jun 15, 20261
Holmes Edward WDirector3,131Jun 15, 20261
Marquet MagdaDirector3,131Jun 15, 20261
Slaoui MoncefDirector–Jun 15, 20261
Markels JohnDirector3,131Jun 15, 20261
Marantz Jing L.Director3,131Jun 15, 20261
Mulroy DennisChief Financial Officer–May 7, 20261
Payne Joseph EPresident and CEO1,480,097Dec 19, 20251
Chivukula PadChief Scientific Officer & COO435,334Dec 19, 20251
Kurata LanceChief Legal Officer–Dec 19, 20251
Roberts JosephController–Dec 19, 20251
Sassine AndyChief Financial Officer221,764Aug 20, 20250
Kummerfeld Keith CSee Remarks950Dec 19, 20230
Ultragenyx Pharmaceutical Inc.Director1,400,000Aug 12, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2025 (view filing)Aug 155 daysSassine AndyChief Financial OfficerPPurchase+1.24K$16.56+$20.5K+0.6%221.8K afterAmended
Oct 16, 2024 (view filing)Oct 151 dayChivukula PadChief Scientific Officer & COOSSale−12.0K$20.76−$249.1K−2.7%435.3K after10b5-1
Jun 14, 2024 (view filing)Jun 122 daysSassine AndyChief Financial OfficerSSale−50.0K$32.03−$1.60M−18.5%220.5K after
Jun 7, 2024 (view filing)Jun 52 daysChivukula PadChief Scientific Officer & COOSSale−114$45.00−$5.13K0.0%447.3K after10b5-1
Jun 4, 2024 (view filing)Jun 31 dayChivukula PadChief Scientific Officer & COOSSale−26.0K$40.01−$1.04M−5.5%447.4K after10b5-1
Mar 27, 2024 (view filing)Mar 252 daysChivukula PadChief Scientific Officer & COOSSale−17.4K$35.02−$610.6K−3.6%473.4K after10b5-1
Mar 21, 2024 (view filing)Mar 192 daysChivukula PadChief Scientific Officer & COOSSale−8.56K$35.01−$299.9K−1.7%490.9K after10b5-1
Nov 3, 2023 (view filing)Nov 12 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$18.72−$93.6K−1.0%499.4K after10b5-1
Oct 4, 2023 (view filing)Oct 22 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$25.61−$128.1K−1.0%504.4K after10b5-1
Sep 5, 2023 (view filing)Sep 14 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$31.45−$157.3K−1.0%509.4K after10b5-1
Aug 3, 2023 (view filing)Aug 12 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$34.91−$174.6K−1.0%514.4K after10b5-1
Jul 18, 2023 (view filing)Jul 144 daysChivukula PadChief Scientific Officer & COOSSale−25.0K$35.01−$875.3K−4.6%519.4K after10b5-1
Jul 18, 2023 (view filing)Jul 144 daysKummerfeld Keith CSee RemarksSSale−6.97K$35.00−$243.9K−88.0%950 after
Jul 7, 2023 (view filing)Jul 34 daysLateChivukula PadChief Scientific Officer & COOSSale−5.00K$28.75−$143.8K−0.9%544.4K after10b5-1
Jun 5, 2023 (view filing)Jun 14 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$27.16−$135.8K−0.9%549.4K after10b5-1
May 12, 2023 (view filing)May 10-112 daysChivukula PadChief Scientific Officer & COOSSale−25.0K$30.08−$751.9K−4.3%554.4K after2 lots10b5-1
May 3, 2023 (view filing)May 12 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$25.93−$129.7K−0.9%579.4K after10b5-1
Apr 19, 2023 (view filing)Apr 181 dayKummerfeld Keith CSee RemarksSSale−6.97K$28.18−$196.4K−88.0%950 after
Apr 5, 2023 (view filing)Apr 32 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$25.38−$126.9K−0.8%584.4K after10b5-1
Mar 8, 2023 (view filing)Mar 62 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$16.07−$80.3K−0.8%589.4K after
Dec 19, 2022 (view filing)Dec 154 daysMarquet MagdaDirectorPPurchase+2.22K$18.00+$40.0K+9.8%24.9K after
Nov 28, 2022 (view filing)Nov 235 daysPayne Joseph EPresident and CEOPPurchase+5.00K$16.51+$82.5K+0.3%1.48M after
Jan 6, 2022 (view filing)Jan 42 daysChivukula PadChief Scientific Officer & COOSSale−8.10K$40.00−$324.0K−1.3%594.4K after
Dec 20, 2021 (view filing)Dec 164 daysChivukula PadChief Scientific Officer & COOSSale−3.63K$40.00−$145.3K−0.6%602.5K after
Dec 10, 2021 (view filing)Dec 82 daysChivukula PadChief Scientific Officer & COOSSale−6.37K$40.00−$254.7K−1.0%606.2K after
Nov 3, 2021 (view filing)Nov 12 daysChivukula PadChief Scientific Officer & COOSSale−10.0K$44.41−$444.1K−1.6%612.5K after
Oct 4, 2021 (view filing)Oct 13 daysChivukula PadChief Scientific Officer & COOSSale−10.0K$44.36−$443.6K−1.6%622.5K after
Sep 2, 2021 (view filing)Sep 11 dayChivukula PadChief Scientific Officer & COOSSale−10.0K$55.86−$558.6K−1.6%632.5K after
Aug 12, 2021 (view filing)Aug 10-112 daysUltragenyx Pharmaceutical Inc.DirectorSSale−800.0K$54.54−$43.6M−36.4%1.40M after2 lots
Aug 5, 2021 (view filing)Aug 32 daysChivukula PadChief Scientific Officer & COOSSale−10.0K$40.07−$400.7K−1.5%642.5K after